Premium
Pooled analysis of Day 100 survival for defibrotide‐treated patients with hepatic veno‐occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation
Author(s) -
Richardson Paul G.,
Smith Angela R.,
Kernan Nancy A.,
Lehmann Leslie,
Soiffer Robert J.,
Ryan Robert J.,
Tappe William,
Grupp Stephan
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16552
Subject(s) - defibrotide , medicine , hepatic veno occlusive disease , dialysis , transplantation , surgery , gastroenterology , organ dysfunction , hematopoietic stem cell transplantation , sepsis
Summary For patients with untreated hepatic veno‐occlusive disease (VOD)/sinusoidal obstruction syndrome (SOS) with multi‐organ dysfunction (MOD), mortality is >80%. We conducted a pooled analysis of three studies that assessed Day 100 survival in relationship to MOD severity, with dialysis and/or ventilator dependence representing the most severe organ dysfunction. All patients in the analysis were diagnosed using Baltimore criteria/biopsy. This analysis of patients with VOD/SOS and MOD after haematopoietic cell transplantation (HCT; n = 651) demonstrated higher Day 100 survival rates amongst defibrotide‐treated patients with VOD/SOS with less versus more severe forms of MOD. Even patients with severe forms of MOD post‐HCT benefitted from defibrotide.